Oryzon Genomics SA (ORY) - Financial Analysis Review

Summary

Oryzon Genomics SA (Oryzon) is a clinical stage biopharmaceutical company that offers development of epigenetics-based therapeutics. The company offers epigenetics, a regulatory system that controls gene expression without affecting the makeup of the genes themselves and provides regulation of gene transcription that has emerged as a key biological determinant of protein production and cellular differentiation. It provides therapeutic programs and collaborative research services. The company offers therapeutic programs for patients with cancers or neurodegenerative disorders. It offers genomics services to the pharmaceutical industry in Europe.

GlobalData's Oryzon Genomics SA (ORY) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years.

Oryzon Genomics SA Key Recent Developments:

Oct 24,2016: ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2016
Aug 08,2016: Oryzon Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2016
May 12,2016: Oryzon Reports First Quarter 2016 Financial Results and Corporate Update
Jan 26,2016: Oryzon Genomics to Present at the Epigenetics in Drug Discovery Workshop
Dec 10,2015: Oryzon Genomics Announces Listing on Madrid Stock Exchange


This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
- Business description - A detailed description of the company's operations and business divisions.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services.
- Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial ratios presented for major public companies in the report include; revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.